AbCellera Biologics (ABCL) is expected to report Q3 2026 revenue of $8.41 million and a consensus EPS loss of $0.18, while currently trading at $11.20—significantly below the $17.20 average analyst price target.
Investors are primarily focused on the full clinical data and follow-up results for AbCellera’s lead internal program, ABCL635, following positive top-line Phase 2 data earlier this year.
The company has aggressively pivoted from a service-based platform to an internal discovery model, which has resulted in a year-over-year revenue decline but enhanced potential for long-term clinical value. With over $670 million in total available liquidity, the market is evaluating whether this strategic shift and elevated R&D spending can successfully deliver a consistent pipeline of clinical-stage candidates.